Last Price
0.111
Today's Change
-0.008 (6.72%)
Day's Change
0.105 - 0.117
Trading Volume
58,508,680
Market Cap
6 Million
Shares Outstanding
57 Million
Avg Volume
21,762,750
Avg Price (50 Days)
0.12
Avg Price (200 Days)
3.54
PE Ratio
0.00
EPS
-288.85
Earnings Announcement
31-Mar-2025
Previous Close
0.12
Open
0.11
Day's Range
0.1051 - 0.1173
Year Range
0.096 - 59.5
Trading Volume
58,508,680
1 Day Change
-6.65%
5 Day Change
-7.89%
1 Month Change
8.73%
3 Month Change
-2.97%
6 Month Change
-90.91%
Ytd Change
-5.13%
1 Year Change
-99.82%
3 Year Change
-99.99%
5 Year Change
-100.00%
10 Year Change
-100.00%
Max Change
-100.00%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.